葵花药业(002737) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥663,495,324.67, a decrease of 56.30% compared to ¥1,518,181,069.65 in the same period last year[5] - Net profit attributable to shareholders was ¥57,111,821.08, down 77.62% from ¥255,183,288.86 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥39,863,790.78, representing an 83.21% decline from ¥237,454,340.04 in the previous year[5] - Basic and diluted earnings per share were both ¥0.10, down 77.27% from ¥0.44 in the same period last year[5] - Net profit for the current period is ¥58,841,384.82, a decline of 78.2% from ¥270,303,238.96 in the previous period[19] Cash Flow - The net cash flow from operating activities was ¥101,710,569.51, a decrease of 50.21% compared to ¥204,290,572.95 in the same period last year[5] - Operating cash flow for the current period is ¥101,710,569.51, a decrease of 50.2% compared to ¥204,290,572.95 in the previous period[21] - Total cash inflow from operating activities is ¥740,744,371.24, down 52.5% from ¥1,556,556,156.54 in the previous period[21] - Cash outflow from operating activities is ¥639,033,801.73, a decrease of 52.8% compared to ¥1,352,265,583.59 in the previous period[21] - Cash flow from investment activities shows a net outflow of ¥200,286,889.86, contrasting with a net inflow of ¥1,006,831,858.31 in the previous period[22] - Cash and cash equivalents at the end of the period stand at ¥937,730,123.72, down 73.1% from ¥3,495,677,467.15 in the previous period[22] - The net increase in cash and cash equivalents for the current period is -¥100,230,574.79, a significant decline from an increase of ¥1,209,972,261.26 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,774,405,931.02, a decrease of 0.88% from ¥5,825,875,967.73 at the end of the previous year[5] - Total liabilities are ¥1,125,647,233.48, down from ¥1,235,876,758.46 in the previous period[16] - Total current assets are reported at ¥3,882,717,982.71, slightly down from ¥3,885,593,091.44 at the beginning of the period[14] - Accounts receivable stand at ¥206,995,831.79, showing a slight decrease from ¥207,740,418.62[14] - Inventory decreased to ¥786,664,048.65 from ¥867,310,798.53, a decline of approximately 9.3%[14] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 55,081[11] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[11] - Shareholders' equity attributable to the parent company increased by 1.30% to ¥4,436,250,289.82 from ¥4,379,138,713.78 at the end of the previous year[5] - Total equity attributable to shareholders of the parent company is ¥4,436,250,289.82, an increase from ¥4,379,138,713.78 in the previous period[16] Expenses and Costs - Total operating costs for the current period are ¥612,330,871.14, down 48.9% from ¥1,198,310,855.92 in the previous period[18] - Research and development expenses for the current period are ¥20,190,757.43, a decrease of 12.3% from ¥22,993,910.90 in the previous period[18] - The company reported a financial asset impairment loss of ¥1,143,003.30 for the current period, compared to ¥1,859,231.83 in the previous period[19] - The company reported a significant reduction in sales expenses by 79.19% to ¥82,215,847.30 from ¥395,103,030.63 in the previous year, due to enhanced cost control[9] Investment Activities - Investment income decreased by 46.27% to ¥2,905,256.09 from ¥5,407,601.03 in the same period last year, primarily due to reduced returns from maturing financial products[9] - The company received ¥1,554,983,011.00 from investment recoveries, which is a substantial increase from ¥1,000,000,000.00 in the previous period[22] Future Plans - The company has announced plans for new product registrations, including Ibuprofen suspension and PEG 3350 powder, expected to enhance market offerings[12] - The company is in the process of increasing capital for its subsidiaries, indicating a strategy for expansion[12] Audit Status - The company has not yet audited the first quarter report for 2025[23]